



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor(s) A. Binggeli, U. Grether, H. Hilpert, G. Hirth, H. Maerki, M. Meyer, P. Mohr

Group:

Serial No. 10/650,434, filed August 28, 2003
Docket No.: 21377 US

Examiner:

For: THIAZOLE DERIVATIVES

INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110
December 4, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents A1 – A7 are not being submitted because they are U.S. Patents.

Documents B1 – B11 and C1 – C24 listed on Form PTO-1449 are enclosed.

Applicants notes that Document A3, U.S. Patent No. 5,089,514 and Document B5, WO 91/19702 are related.



PTO/SB/21 (01-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/650,434
	Filing Date	August 28, 2003
	First Named Inventor	Binggeli
	Art Unit	
	Examiner Name	
Total Number of Pages in This Submission	Attorney Docket Number	21377 US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks USPTO Form 1449; References	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual	Eileen M. Ebel	
Signature		
Date	December 4, 2003	

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on this date <u>December 4, 2003</u>	
Typed or printed	Eileen M. Ebel
Signature	
Date	12/4/2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Serial No. 10/650,434
Filed: August 28, 2003

For WO 00/08002, which is provided here as Cite No. B4, an abstract is included which is STN International CAPLUS Database, Accession No. 2000:117035, provided here as Cite No. C21.

Consideration of all the documents cited on Form PTO-1449 is requested.

Since the Information Disclosure Statement is submitted before receipt of a first Office Action on the merits, it is believed that no fee is due.

If a fee is owing, please charge our deposit account no. 08-2525.

Respectfully submitted,



Attorney for Applicant(s)
Eileen M. Ebel
(Reg. No. 37,316)
340 Kingsland Street
Nutley, New Jersey 07110
Telephone: (973) 235-4391
Telefax: (973) 235-2363

136259



Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Application Number	10/650,434
				Filing Date	August 28, 2003
				First Name Inventor	Binggeli
				Group Art Unit	
				Examiner Name	
Sheet	1	Of	2	Attorney Docket Number	21377 US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	C1	Keller and Wahli: Trends Endocrin. Metab. (1993); 4:291-296	
	C2	MacDougald and Lane: Current Biology Vol. 5 pp. 618-621 (1995)	
	C3	Guerre-Millo, et. al.; J Biol Chem 2000; 275: 16638-16642	
	C4	Balfour, et. al.; Drugs 57 (1999) 921-930	
	C5	Haigh et. al., Tetrahedron: Asymmetry, 10, pp. 1353-1367	
	C6	Gotteland et al., Synlett, 9 pp. 931-932 (1995)	
	C7	Hulin et al., J. Med. Chem., 39, pp. 3897-3907 (1996)	
	C8	Nicolaou et al., J. Am. Chem. Soc., 122, pp. 3830-3838 (2000)	
	C9	Nichols et al., Anal. Biochem., 257, pp. 112-119 (1998)	
	C10	Einsiedel et. al., Bioorg. Med. Chem. Lett., 10, pp. 2041-2044 (2000)	
	C11	Goto et al., Chem. Pharm. Bull., 19, pp. 2050-2057 (1971)	
	C12	Reichstein et al., Helvetica Chimica Acta, 16, pp. 121-129 (1933)	
	C13	Diels et al., chem.. Ber., 48, pp. 897-905 (1915)	
	C14	Wightman et al., J. Org. chem., 43, pp. 2167-2170 (1978)	
	C15	Musser et al., J. Med. Chem. 30, pp. 62-67 (1987)	
	C16	Rahman et al., J. Chem. Soc. Perkin Trans. 1, 12, pp. 2973-2977 (1983)	
	C17	Kelly et. al., J. Am. Chem. Soc., 110, pp. 6471-6480 (1988)	
	C18	Kneen et al., Synthetic Communications, 16, pp. 1635-1640 (1986)	
	C19	Kim et al., Can. J. Chem., 60, pp. 2093-2098 (1982)	
	C20	Pàrkányi et al., Monatsh. Chem., 123, pp. 637-645 (1992)	
	C21	STN International @ CAPLUS Database, Accession No. 2000; 117035; Collins et al., WO 2000008002, abstract	
	C22	Malamas, MS et al, Eur. J. Med. Chem. Vol. 36, No. 1 (2001) pp. 31-42	
	C23	Hulin, B. et al., Current Pharmaceutical Design, Vol.2 (1996) pp. 85-102	
	C24	Oplinger, et. al., ACS National Meeting, San Diego, April 1-5, 2001, Poster 238, Division of Medicinal Chemistry, Section C	
Examiner Signature			DATE CONSIDERED

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Unique citation designation number. ² Applicant is to place a check mark here if English language Translation or abstract is attached.

136252

O I P F
 DEC 08 2003
 JCT103
 PATENT & TRADEMARK

Substitute for form 1449A/PTO				Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Application Number	10/650,434		
				Filing Date	August 28, 2003		
				First Name Inventor	Binggeli		
				Group Art Unit			
				Examiner Name			
Sheet	1	of	2	Attorney Docket Number	21377 US		
U.S. PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY		
		Number	Kind Code ² (if known)				
	A1	5,856,529		Bristol-Myers Squibb Company	01/05/1999		
	A2	6,121,397		Xerox Corporation	09/19/2000		
	A3	5,089,514		Bernard Hulin	02/18/1992		
	A4	4,011,326		Jensen	03/08/1977		
	A5	6,291,685		Junghans, et. al.	09/18/2001		
	A6	6,441,185		Kühnle, et. al.	08/27/2002		
	A7	5,599,826		Mertens, et. al.	02/04/1997		
FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
	B1	EP	1 078 923		F. Hoffmann-La Roche A.G.	02/28/2001	
	B2	WO	99/10339		Pfizer Products Inc.	03/04/1999	
	B3	WO	02 16331		Eli Lilly & Company	02/28/2002	
	B4	WO	00 08002		Glaxo Group Limited	02/17/2000	X
	B5	WO	91/19702		Pfizer Inc.	12/26/1991	
	B6	WO	94/01420		Smithkline Beecham PLC.	01/20/1994	
	B7	WO	94/13650		Smithkline Beecham PLC.	06/23/1994	
	B8	WO	95/17394		Smithkline Beecham PLC	06/29/1995	
	B9	WO	97/25042		Smithkline Beecham PLC	07/17/1997	
	B10	WO	99/08501		Dr. Reddy's Research Foundation	02/25/1999	
	B11	EP	0903343		SSP Co., Ltd.	03/24/1999	
Examiner Signature		Date Considered					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.